Genzyme has begun shipping Fabrazyme (agalsidase beta) from their newly approved manufacturing plant in Framingham, Masschusetts. This is an important step in restoring supplies globally and in meeting the needs of patients. Patients in the US are now able to return to full dosing in March. In addition, all new patients are eligible to begin Fabrazyme treatment, at full dosing levels.
Fabrazyme is indicated for the treatment of Fabry disease, an inherited condition that is characterized by excessive accumulation of the lipid GL-3 in various organs and tissues, which over time can cause renal, cardiac and cerebrovascular events.
Fabrazyme is available from Genzyme in 5mg and 35mg vials.
For more information visit www.genzyme.com.